CLINICAL TRIALS PROFILE FOR COSENTYX

All Clinical Trials for COSENTYX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02144857 ↗	Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis	Recruiting	University of Athens	Phase 4	2014-05-30	Psoriasis has been associated with an increasing risk for atherosclerosis. The investigators investigated whether surrogate markers of subclinical atherosclerosis, vascular dysfunction and myocardial dysfunction are impaired in patients with psoriasis compared to normal controls ,coronary artery disease patients and untreated hypertension subjects. The investigators also examined the effect of treatment with biological vs no biological agents on vascular and LV function in psoriasis.
NCT02592018 ↗	Immunologic Response to Secukinumab in Plaque Psoriasis	Completed	Novartis Pharmaceuticals	Phase 4	2016-10-01	This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.
NCT02592018 ↗	Immunologic Response to Secukinumab in Plaque Psoriasis	Completed	University of California, San Francisco	Phase 4	2016-10-01	This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.
NCT02778711 ↗	Anti-IL-17 a New Treatment for Contact Dermatititis	Unknown status	Tanja Todberg, MD	Phase 3	2016-01-01	The purpose of this study is to assess the efficacy of anti-IL 17 treatment (secukinumab) in patients with known severe allergic contact dermatitis (ACD).
NCT02854163 ↗	Effect of Secukinumab in the Treatment of Psoriatic Arthritis	Completed	Novartis	Phase 2	2016-10-15	The investigators propose an open label pragmatic clinical and laboratory study designed to investigate, in detail, the clinical and molecular effects of Interleukin 17 (IL-17) and inhibition of IL-17 with secukinumab, on neutrophil function in vitro and ex vivo. As secondary, exploratory objectives, the investigators will utilise the fact that secukinumab is to be administering to 20 patients with Psoriatic Arthritis (PsA) and investigate whether there is any relationship between vitamin D status and response to secukinumab, with respect to efficacy and adverse events. The results of this secondary exploratory analysis will inform the design of a larger, definitive study.
NCT02854163 ↗	Effect of Secukinumab in the Treatment of Psoriatic Arthritis	Completed	University of Liverpool	Phase 2	2016-10-15	The investigators propose an open label pragmatic clinical and laboratory study designed to investigate, in detail, the clinical and molecular effects of Interleukin 17 (IL-17) and inhibition of IL-17 with secukinumab, on neutrophil function in vitro and ex vivo. As secondary, exploratory objectives, the investigators will utilise the fact that secukinumab is to be administering to 20 patients with Psoriatic Arthritis (PsA) and investigate whether there is any relationship between vitamin D status and response to secukinumab, with respect to efficacy and adverse events. The results of this secondary exploratory analysis will inform the design of a larger, definitive study.
NCT03041038 ↗	The Efficacy and Safety of Secukinumab in Patients With Ichthyoses	Completed	Icahn School of Medicine at Mount Sinai	Phase 2	2016-12-01	The ichthyoses are a group of lifelong genetic disorders which share characteristics of generalized skin thickening, scaling and underlying cutaneous inflammation. There are no therapies based on growing understanding of what causes the disease. However, there have been recent discoveries of marked elevations in expression of interleukin-17A (IL-17A) and IL-17-related cytokines in the skin of individuals with ichthyosis, which may explain the inflammation. Investigators propose that IL-17-targeting therapeutics will safely suppress the inflammation and possibly the other features of ichthyosis, improving quality of life.

Clinical Trial Conditions for COSENTYX

Condition Name

Condition Name for COSENTYX
Intervention	Trials
Psoriasis	11
Psoriatic Arthritis	4
Plaque Psoriasis	2
Healthy	2

Condition MeSH

Condition MeSH for COSENTYX
Intervention	Trials
Psoriasis	14
Arthritis, Psoriatic	4
Arthritis	4
Dermatitis, Exfoliative	2

Clinical Trial Locations for COSENTYX

Trials by Country

Trials by Country for COSENTYX
Location	Trials
United States	54
Canada	9
Germany	8
Australia	6
Poland	6

Trials by US State

Trials by US State for COSENTYX
Location	Trials
New York	4
Illinois	3
California	3
Massachusetts	3
Minnesota	3

Clinical Trial Progress for COSENTYX

Clinical Trial Phase

Clinical Trial Phase for COSENTYX
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	5
Phase 2	7

Clinical Trial Status

Clinical Trial Status for COSENTYX
Clinical Trial Phase	Trials
Completed	10
Recruiting	9
Not yet recruiting	5

Clinical Trial Sponsors for COSENTYX

Sponsor Name

Sponsor Name for COSENTYX
Sponsor	Trials
Novartis	6
Novartis Pharmaceuticals	4
Janssen Research & Development, LLC	3

Sponsor Type

Sponsor Type for COSENTYX
Sponsor	Trials
Other	29
Industry	21

Clinical Trials Update, Market Analysis, and Projection for COSENTYX (Secukinumab)

Last updated: October 26, 2025

Introduction

COSENTYX (secukinumab) is a biologic monoclonal antibody developed by Novartis, approved for the treatment of several autoimmune conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. As a selective interleukin-17A (IL-17A) inhibitor, COSENTYX has established a significant position in the immunology therapeutic landscape. This report provides a comprehensive update on ongoing clinical trials, analyzes market dynamics, and projects the future demand trajectory of COSENTYX.

Clinical Trials Update

Current Clinical Trials Landscape

As of 2023, COSENTYX remains at the forefront of clinical research, with multiple ongoing studies exploring its efficacy, safety, and potential new indications.

• Approved Indications: COSENTYX currently holds FDA and EMA approvals for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. These indications are supported by robust phase III clinical trials, demonstrating high efficacy and favorable safety profiles.

• Additional Indications & Trials: Novartis continues to expand COSENTYX's therapeutic scope. Notable among ongoing studies are trials investigating its use in:

  • Hidradenitis Suppurativa: Phase II/III trials are examining efficacy and safety profiles, aiming to address an unmet dermatological need.
  • Uveitis: Multiple phase II trials are assessing its potential in non-infectious intermediate and posterior uveitis.
  • COVID-19: Preliminary investigations evaluated IL-17A inhibition’s role in mitigating cytokine storms in hospitalized COVID-19 patients; however, these did not progress further.

Recent Clinical Findings

Recent data from pivotal trials reinforce COSENTYX's efficacy:

• In COMET-1 and COMET-2 (psoriasis studies), over 80% of patients achieved PASI 75 and PASI 90 responses at week 12, with sustained results up to week 52.
• The FUTURE series trials in psoriatic arthritis confirmed prominent improvements in joint and skin outcomes, with rapid onset of action.
• Safety profiles remain consistent with previous data; common adverse events include nasopharyngitis and mild infections, with low rates of serious adverse effects.

Future Clinical Directions

Novartis is prioritizing real-world evidence studies and head-to-head comparative trials against other biologics like secukinumab vs. ixekizumab or brodalumab, aiming to refine positioning strategies and optimize therapeutic protocols. The company also explores dosing flexibility, including subcutaneous administration at extended intervals, to improve patient adherence.

Market Analysis

Market Size and Growth Trends

The global biologics market targeting autoimmune and inflammatory diseases has experienced exponential growth:

• Market Valuation: As of 2023, the global IL-17 inhibitors market is valued at approximately $18 billion, with an expected compound annual growth rate (CAGR) of 8-10% over the next five years [1].

• Major Players: Besides Novartis (COSENTYX), key competitors include Eli Lilly's TALTZ (ixekizumab), AstraZeneca's Siliq (brodalumab), and Biogen/AbbVie’s Skyrizi (risankizumab), highlighting intense competitive pressure.

• Market Dynamics: The rising prevalence of psoriasis (~125 million globally) and psoriatic arthritis (estimated at 0.3-1%) underscores significant growth potential. Moreover, increased diagnosis rates, expansion into emerging markets, and formulary inclusions contribute to expanding the target population.

Market Penetration and Revenue

• Current Revenue: COSENTYX generated approximately $3.9 billion worldwide in 2022, representing a growth of 16% year-over-year (YoY) [2].

• Market Penetration: In dermatology, COSENTYX holds approximately 35-40% of the biologic psoriasis market share, reflecting strong prescriber preference but facing competition from other IL-17 inhibitors and IL-23 targeted therapies.

• Geographical Distribution: North America remains the largest single market, accounting for over 50% of revenues, driven by high disease awareness and reimbursement access. Europe and Asia-Pacific are rapidly expanding markets, propelled by unmet needs and healthcare infrastructure upgrades.

Challenges and Opportunities

• Patent Expiry & Biosimilars: Novartis's patent protections extend into the late 2020s; however, biosimilar development in key markets like Europe threatens future market share.

• Pricing & Reimbursement: Cost pressures and payer negotiations influence access. COSENTYX's premium pricing model requires demonstrating superior efficacy and safety to maintain competitiveness.

• Innovation & Line Extension: Development of extended dosing schedules and combination therapies present growth opportunities to optimize patient outcomes and adherence.

Projection and Outlook

Market Growth Forecast

Projected compound annual growth rates of 8-10% through 2030 suggest the IL-17 inhibitors market will surpass $35 billion globally, with COSENTYX expected to sustain or increase its market share owing to:

• Robust pipeline and indications expansion: The ongoing trials in hidradenitis suppurativa and uveitis hold the potential to enlarge its market scope.

• Adoption in underserved markets: Growing healthcare infrastructure in emerging markets will contribute to increased prescriptions.

• Enhanced formulations: Subcutaneous dosing flexibility aimed at improving patient compliance and reducing healthcare system burdens.

Revenue Projections

Estimating compound growth and expanding indications, COSENTYX revenue is projected to reach $6-8 billion annually by 2025, driven by:

• Increased adoption in psoriatic arthritis and ankylosing spondylitis.
• Greater penetration into new markets.
• Potential label expansions contingent on positive clinical trial outcomes.

Strategic Considerations

• Competitive positioning: Maintaining efficacy and safety advantages over competitors, alongside strategic pricing, will be critical.
• Clinical pipeline: Active exploration of novel indications and formulations could solidify the brand’s foothold.
• Regulatory landscape: Navigating patent expirations and biosimilar entry requires proactive legal and commercial strategies.

Key Takeaways

• Clinical efficacy of COSENTYX remains strong, with recent pivotal trials affirming its role in treating multiple autoimmune diseases.
• Market expansion continues, fueled by increasing prevalence, expanding indications, and geographical growth, especially in emerging economies.
• Competitive dynamics are intense, necessitating ongoing innovation and portfolio diversification.
• Revenue outlook is optimistic, with projections reaching $6-8 billion annually by 2025, supported by existing demand and pipeline developments.
• Strategic focus should include enhancing patient adherence, expanding indications, and navigating biosimilar threats.

---

Frequently Asked Questions (FAQs)

1. What are the latest approved indications for COSENTYX?
   COSENTYX is approved for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Clinical trials are ongoing for additional conditions like hidradenitis suppurativa and uveitis.

2. How does COSENTYX compare to its competitors?
   COSENTYX demonstrates high efficacy and a favorable safety profile comparable with other IL-17 inhibitors like secukinumab (brand name remaining the same but by different companies) and ixekizumab. Choice often depends on patient response, dosing preferences, and formulary access.

3. What are the upcoming clinical trials for COSENTYX I should watch?
   Novartis continues exploring COSENTYX for hidradenitis suppurativa and uveitis, with results potentially influencing future approval and adoption.

4. What are the key drivers of market growth for COSENTYX?
   Rising disease prevalence, new indications, geographical expansion, and continuous clinical research are primary drivers of growth.

5. What challenges could impact COSENTYX’s market performance?
   Patent expirations, biosimilar competition, pricing pressures, and shifting healthcare policies may pose risks to market share and revenue.

---

References

1. Grand View Research. IL-17 Inhibitors Market Size, Share & Trends Analysis Report. 2023.
2. Novartis Annual Report 2022. Financial and Business Highlights.